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ABSTRACT
Clinical manifestations of pancreatic cancer often do not occur until the cancer
has undergone metastasis, resulting in a very low survival rate. In this study, we
investigated whether salivary bacterial profiles might provide useful biomarkers for
early detection of pancreatic cancer. Using high-throughput sequencing of bacterial
small subunit ribosomal RNA (16S rRNA) gene, we characterized the salivary micro-
biota of patients with pancreatic cancer and compared them to healthy patients and
patients with other diseases, including pancreatic disease, non-pancreatic digestive
disease/cancer and non-digestive disease/cancer. A total of 146 patients were en-
rolled at the UCSD Moores Cancer Center where saliva and demographic data were
collected from each patient. Of these, we analyzed the salivary microbiome of 108
patients: 8 had been diagnosed with pancreatic cancer, 78 with other diseases and 22
were classified as non-diseased (healthy) controls. Bacterial 16S rRNA sequences were
amplified directly from salivary DNA extractions and subjected to high-throughput
sequencing (HTS). Several bacterial genera differed in abundance in patients with
pancreatic cancer. We found a significantly higher ratio of Leptotrichia to Porphy-
romonas in the saliva of patients with pancreatic cancer than in the saliva of healthy
patients or those with other disease (Kruskal–Wallis Test; P < 0.001). Leptotrichia
abundances were confirmed using real-time qPCR with Leptotrichia specific primers.
Similar to previous studies, we found lower relative abundances of Neisseria and
Aggregatibacter in the saliva of pancreatic cancer patients, though these results were
not significant at the P < 0.05 level (K–W Test; P = 0.07 and P = 0.09 respectively).
However, the relative abundances of other previously identified bacterial biomarkers,
e.g., Streptococcus mitis and Granulicatella adiacens, were not significantly different
in the saliva of pancreatic cancer patients. Overall, this study supports the hypothesis
that bacteria abundance profiles in saliva are useful biomarkers for pancreatic cancer
though much larger patient studies are needed to verify their predictive utility.
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INTRODUCTION
In the United States, approximately 40,000 people die every year from pancreatic
adenocarcinoma, making it the fourth leading cause of cancer related death. Patients
diagnosed in the early stage of pancreatic cancer have a 5-year survival rate of 24%,
compared to 1.8% when diagnosed in the advanced stage (Li et al., 2004). Clinical
manifestations of pancreatic cancer do not appear until after the cancer has undergone
metastasis (Holly et al., 2004), emphasizing the need for early detection biomarkers.
The etiology of pancreatic cancer remains elusive, with cigarette smoking being the
most established risk factor (Vrieling et al., 2010; Nakamura et al., 2011; Fuchs, Colditz
& Stampfer, 1996; Zheng et al., 1993), although links have also been made to diabetes
(Haugvik et al., 2015; Liu et al., 2015), obesity (Bracci, 2012), and chronic pancreatitis
(Malka et al., 2002). Recent research has also shown that men with periodontal disease
have a two-fold greater risk of developing pancreatic cancer after adjusting for smoking,
diabetes, and body mass index (Michaud et al., 2007).
The human oral cavity harbors a complex microbial community (microbiome) known
to contain over 700 species of bacteria, more than half of which have not been cultivated
(Aas et al., 2005). Researchers have identified a core microbial community in healthy
individuals (Zaura, Keijser & Huse, 2009) and shifts from this core microbiome have
been associated with dental carries and periodontitis (Berezow & Darveau, 2011). The
composition of bacterial communities in saliva seems to reflect health status under certain
circumstances (Yamanaka et al., 2012), making the analysis of salivary microbiomes a
promising approach for disease diagnostics. A study by Mittal et al. (2011) found that
increases in the numbers of Streptococcus mutans and lactobacilli in saliva have been
associated with oral disease prevalence, while another study showed that high salivary
counts of Capnocytophaga gingivalis, Prevotella melaninogenica and Streptococcus mitis may
be indicative of oral cancer (Mager et al., 2005).
A recent study by Farrell et al. (2012) suggested that the abundances of specific salivary
bacteria could be used as biomarkers for early-stage pancreatic cancer. Using the Human
Oral Microbe Identification Microarray (HOMIM), researchers observed decreased levels
of Neisseria elongata and Streptococcus mitis in patients with pancreatic cancer compared
with healthy individuals, while levels of Granulicatella adiacens were significantly higher
in individuals with pancreatic cancer (Farrell et al., 2012). The HOMIM’s ability to
detect 300 of the most prevalent oral bacterial species has made it a suitable method for
assessing community profiles at the phylum level as well as many common taxa at the genus
level. However, the HOMIM microarray method fails to detect approximately half of the
bacterial species commonly present in saliva (Ahn et al., 2011).
In this study, we applied high-throughput sequencing (HTS) of the bacterial small-
subunit ribosomal RNA (16S rRNA) genes to determine the salivary profiles of patients
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with and without pancreatic cancer. The use of HTS to sequence 16S rRNA bacterial
genes from entire salivary microbial communities allows for a more comprehensive
profile of the microbiome in health and disease (Kuczynski, Lauber & Walters, 2011).
During this study, we collected 146 saliva samples from patients at the UCSD Moores
Cancer Center. HTS was used to characterize the salivary microbiome of patients with
pancreatic cancer and compare them to patients with other diseases (including pancreatic
disease, non-pancreatic digestive disease/cancer and non-digestive disease/cancer) as well
as non-diseased (healthy) controls. This allowed us to test the hypothesis that patients
with pancreatic cancer may have a distinct microbial community profiles compared to
non-diseased controls and to other forms of digestive and non-digestive diseases. Our
results demonstrated that patients with pancreatic cancer had a significantly higher
abundance ratio of particular bacterial genera.
MATERIALS AND METHODS
Sample collection and patient information
This study was approved by the University of California San Diego (UCSD) and San
Diego State University (SDSU) joint Institutional Review Board (IRB Approval #120101).
Patients recruited for the study were being clinically evaluated at the UCSD Moores Cancer
Center or were undergoing endoscopy procedures by UCSD Gastroenterologists in the
Thornton Hospital Pre-Procedure Clinic between May 2012 and August 2013. All patients
were required to fast for 12-hours prior to cancer evaluation and endoscopy procedures.
To avoid bias during enrollment, the research coordinator responsible for recruiting
participants was unaware of patient diagnosis at time of sample collection. Consenting
participants were provided with IRB-approved consent forms, and HIPAA forms, as well
as an optional, voluntary written survey in which they could share relevant information
about antibiotic, dental and smoking history. All participants gave informed consent and
their identities were withheld from the research team. Each subject was free to withdraw
from the study at any time. Participants were asked to give a saliva sample into a 50 mL
conical tube. If the amount of saliva exceeded 55 uL, 10 uL was transferred into tube
containing Brain-Heart Infusion media (BHI) and glycerol for future culturing. The
remaining saliva was broken up into 55 uL aliquots and stored in sterile cryovials. Both
BHI and saliva samples were then immediately stored at−80 ◦C until further processing.
Of the 146 participants, three subjects voluntarily withdrew and seven were not
included in the study due insufficient production of saliva (<55 uL) leaving 136 saliva
samples. After sample collection, the research coordinator accessed the participants’
medical records electronically for patient diagnosis information that was included under
a novel subject ID number. Diagnosis was used to determine health status and assess
the stage of disease when each sample was taken. The various diagnoses were grouped
into the following categories: pancreatic cancer, other disease (including pancreatic
disease, non-pancreatic digestive disease/cancer and non-digestive disease/cancer), and
healthy (non-diseased) controls. Healthy individuals were defined as participants with
no documented chronic digestive or non-digestive disease, and a 5-year resolution of any
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previously documented digestive or non-digestive disease. Exclusion criteria included
participants undergoing active chemotherapy or radiation therapy or use of antibiotics two
weeks prior to saliva collection as well as invasive surgery in the past year.
DNA isolation, PCR and 16S rRNA sequencing
Bacterial DNA was extracted directly from 50 uL of patient saliva using the MoBio
PowerSoil DNA Extraction Kit (Catalogue 12888-05, Mo Bio Laboratories, Carlsbad,
CA, USA) following the manufacturer’s protocol. Genomic DNA was quantified using the
NanoDropTM Spectrophotometer and stored at−20 ◦C.
The 16S ribosomal RNA (rRNA) amplicon region was amplified using barcoded
‘universal’ bacterial primer 515F (5′-AATGATACGGCGACCACCGAGATCTACAC
TATGGTAATT GT GTGCCAGCMGCCGCGGTAA-3′) and 806R (5′-CAAGCAGAAGA
CGGCATACGAGAT XXXXXXXXXXXX AGTCAGTCAG CC GGACTACHVGGGTWT
CTAAT-3′) (X’s indicate the location of the 12-bp barcode) with Illumina adaptors used
by the Earth Microbiome Project (http://www.earthmicrobiome.org/emp-standard-
protocols/16s). The barcoded primers allow pooling of multiple PCR amplicons in a
single sequencing run. PCR was carried out using the reaction conditions outlined by the
Earth Microbiome Project. Thermocycling parameters were as follows: 94 ◦C for 3 min
(denaturing) followed by amplification for 35 cycles at 94 ◦C for 45 s, 50 ◦C for 60 s and
72 ◦C for 90 s, and a final extension of 72 ◦C for 10 min (Caporaso et al., 2011). PCR
amplicons were then sequenced on the Illumina MiSeq platform at the Argonne National
Laboratory Core sequencing facility (Lemont, IL).
Sequence analysis
16S rRNA sequences were de-multiplexed using the Quantitative Insights Into Microbial
Ecology (QIIME v.1.8.0, http://www.qiime.org) pipeline. Sequences were grouped into
operational taxonomic units (OTUs) at 97% sequence similarity using the Greengenes
reference database. OTUs that did not cluster with known taxa at 97% identity or higher
in the database were clustered de novo (UCLUST (Edgar, 2010). Representative sequences
for each OTU were then aligned using PyNast (Caporaso, Bittinger & Bushman, 2010),
and taxonomy was assigned using the RDP classifier (Version 2.2) (Cole et al., 2003). A
phylogenetic tree was built using FastTree (Price, Dehal & Arkin, 2009). Before performing
downstream analysis, patient samples were rarefied to 100,000 sequences per sample,
singletons and OTUs present in <25% of samples were removed prior to rarefaction.
Chimeric sequences were identified using ChimeraSlayer in QIIME, as well as with
DECIPHER (Wright, Yilmaz & Noguera, 2012), and subsequently removed. Alpha diversity
metrics were computed using QIIME. Beta diversity distance between samples (weighted
and unweighted UniFrac) were computed and used to account for both differences in
relative abundance of taxa and phylogeny (Va´zquez-Baeza et al., 2013). Beta diversity
comparisons were done using analysis of similarities (ANOSIM). We also tested whether
there were significant differences in abundance ratios of particular genera between our
different categories with GraphPad Prism version 6.0 using the Kruskal–Wallis test
followed by Dunn’s multiple comparison correction. Statistical significance was accepted
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at a p < 0.05. Analysis and identification of potential contaminants was done using
SourceTracker (Knights et al., 2011).
Quantitative PCR (qPCR)
Leptotrichia abundance was determined using qPCR. Briefly, for each sample we
estimated Leptotrichia abundance using Leptotrichia specific 16S primers and normalized
their values to overall bacterial abundance estimated using qPCR with universal
bacterial 16S primers (5′-TCCTACGGGAGGCAGCAGT-3′ forward primer, and
5′-GGACTACCAGGGTATCTAATCCTGTT-3′ reverse primer) developed by Nadkarni
et al. (2002). qPCR was performed on a Bio-Rad CFX96 TouchTM Real-Time PCR
Detection Instrument. The maximum Ct (threshold cycle) for the universal 16S primers
was set to 35 cycles and Ct levels above this threshold were considered background noise.
Genus-specific primers for amplification of Leptotrichia were designed using 16S rRNA
sequences obtained from the RDP classifier (Version 2.2) (Cole et al., 2003). Primer3
online software was used for primer selection, and conditions were settled following
the recommendations of Thornton & Basu (2011). The Leptotrichia forward primer
sequence (5′-GGAGCAAACAGGATTAGATACCC-3′) and the Leptotrichia reverse primer
sequence (5′-TTCGGCACAGACACTCTTCAT-3′) generated an amplicon of 87 bp. The
PCR reaction contained 1 uM of both forward and reverse Leptotrichia primers with
thermocycling parameters of 50 ◦C for 2 min, 95 ◦C for 10 min and 40 cycles of 95 ◦C
for 15 s and 62.5 ◦C for 1 min. The amplification reactions for the universal primers and
Leptotrichia primers were carried out in at least duplicate using 25 uL of SYBR Green
Master Mix (Bio-Rad) and 0.85 ng/uL of extracted DNA as template. Various online
tools, including In silico PCR Amplification (Bikandi et al., 2004) and Ribosomal Database
Project (Cole et al., 2003) were used to check the specificities of the oligonucleotide primer
sequences for the target organism. A saliva sample was sequenced (Eton Bioscience, San
Diego, CA) using our novel primers and primer specificity was further confirmed with a
16S rRNA database BlastN search.
RESULTS
Salivary microbial diversity profiles were generated for a total of 108 patients. 8 patients
were diagnosed with pancreatic cancer (P), 78 were diagnosed with other diseases
(including cancer) (O), and 22 were considered healthy (non-diseased) controls (H).
Table 1 details the individual clinical characteristics, including, gender and ethnicity. Of
the 108 patients, 23 patients in pancreatic, digestive, and non-digestive disease categories
were diagnosed with having cancer. Table 2 details the types of cancer, as well as category
groupings and the mean age of the cancer patients in each category.
Illumina sequencing yielded approximately 6.8 million sequences across all sam-
ples. The sequences are available on FigShare (http://dx.doi.org/10.6084/m9.figshare.
1422174) along with the mapping file (http://dx.doi.org/10.6084/m9.figshare.1422175).
An analysis of potential sample contamination using SourceTracker (Knights et al., 2011)
identified some evidence of human skin and/or environmental contamination. The
sequences associated with OTUs identified as contaminants, mostly Staphylococcus (skin)
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Table 1 Clinical characteristics of study sample (n= 108).
Demographics Pancreatic cancer (P) Other disease (O) Healthy control (H) Total
n= 8 n= 78 n= 22 n= 108
Sex
Male 6 38 12 56
Female 2 40 10 52
Ethnicity
Caucasian 6 56 15 77
Hispanic 2 6 5 13
Asian 0 4 1 5
Unknown 0 12 1 13
Table 2 Types of identified cancers (n= 23).
Cancer by category Age mean N
Pancreas (n= 8) 71.1
Pancreatic cancer 8
Digestive (n= 9) 64.7
Ampullary 3
Esophageal 3
Stomach 1
Rectal 2
Non-digestive (n= 6) 54.8
Breast 1
Skin 1
Testicular 1
Thyroid 3
and Cyanobacteria (chloroplasts), were removed from all subsequent analyses. From these
data, we identified a total of 12 bacterial phyla and 139 genera. Proteobacteria, Actinobac-
teria, Bacteroidetes, Firmicutes, and Fusobacteria were the 5 major phyla, accounting for
99.3% of oral bacteria (Fig. 1). The mean relative abundance of Proteobacteria was lower
in pancreatic cancer patients relative to other sample categories, while Firmicutes tended
to be higher, though these were not significant after adjusting for multiple comparisons
(FDR). The pancreatic cancer group also had higher levels of Leptotrichia, as well as lower
levels of Porphyromonas, and Neisseria (Fig. 2). In general, multi-level taxonomic profiles
of the healthy group resembled the ‘other’ disease group, while the pancreatic cancer group
was readily distinguishable (Fig. S1). However, there were no significant differences among
the three main groupings (H, O, and P) in either beta diversity (ANOSIM; P = 0.1) or
alpha diversity (Chao1, K–W test; P = 0.6; Faith’s PD, K–W test; P = 0.56).
As in previous studies by Farrell et al. (2012) and Lin et al. (2013), we saw lower
relative abundances of Neisseria and Aggregatibacter, although these differences were not
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Figure 1 Relative abundance of phyla identified in patient saliva summarized by diagnosis group. Rel-
ative abundance of phyla in oral communities from 108 study patients summarized by diagnosis group
(H, healthy control; O, other disease; and P, pancreatic cancer).
Figure 2 Mean relative abundances of particular genera in pancreatic cancer patients (P) compared
to healthy (H) and other disease (O) patient groups. Relative abundances of genera in oral communities
from 108 patients. Arrows point to specific genera that showed interesting trends across diagnosis groups.
significant (K–W test; P = 0.07 and P = 0.09 respectively). Bacteriodes was more abundant
in pancreatic cancer patients compared to healthy individuals, similar to what Lin et
al. observed, although this too was not significant (K–W test; P = 0.27). We did not see any
difference in the relative abundance of Streptococcus or Granulicatella, which were shown to
differ in a prior pancreatic cancer study (Farrell et al., 2012). Additional analytical targets
were based on a preliminary study consisting of our first 61 saliva samples (including 3
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Figure 3 Abundance ratio of Leptotrichia to Porphyromonas between different patient cate-
gories. Each symbol represents the ratio of Leptotrichia Oral Taxon 221 and Leptotrichia hongkongenesis
to Porphyromonas for an individual patient (n = 108). Patients are grouped into 3 different categories
depending on their diagnosis: healthy control (H), other diseases (including cancer) (O), and pancreatic
cancer (P). Horizontal bar and error bars represent the mean and SEM, respectively. ∗∗∗p < 0.001
(Kruskal–Wallis test followed by Dunn’s multiple-comparison test).
from pancreatic cancer patients), which showed significantly higher Leptotrichia and lower
Porphyromonas in pancreatic cancer patient saliva.
The abundance ratio of Leptotrichia, specifically two OTUs (arbitrarily named OTU
31235 and OTU 4443207), to Porphyromonas was significantly higher in pancreatic cancer
patients (Fig. 3). A BLAST comparison of these OTUs to the 16S sequence in the Human
Oral Microbiome database (Chen et al., 2010) (HOMD RefSeq Version 13.2) found OTU
31235 to be 100% similar to Leptotrichia sp. Oral taxon 221, while OTU 4443207 was
99.3% similar to Leptotrichia hongkongensis. We found a strong positive correlation (Pear-
son’s correlation r = 0.903, P = 0.0000001) between Leptotrichia abundances obtained
from 16S rRNA sequencing (OTU relative abundances) and from real-time qPCR (Fig. 4).
DISCUSSION
Our analysis of salivary microbial profiles supports prior work suggesting that salivary
microbial communities of patients diagnosed with pancreatic cancer are distinguishable
from salivary microbial communities of healthy patients or patients with other diseases,
including non-pancreatic cancers. At the phylum level, pancreatic cancer patients tended
to have higher proportions of Firmicutes and lower proportions of Proteobacteria (Fig. 1).
At finer taxonomic levels, we observed differences in the mean relative abundances of
particular genera in pancreatic cancer patients compared to other patient groups (Fig. 2).
For instance, there was a higher proportion of Leptotrichia in pancreatic cancer patients,
while the proportion of Porphyromonas and Neisseria were lower in these patients.
The most striking difference we found between the microbial profiles of pancreatic
cancer patients and other patient groups was in the ratio of the bacterial genera
Leptotrichia and Porphyromonas (LP ratio) (Fig. 3). The LP ratio had been identified
as a potential biomarker from a preliminary analysis and an analysis of the full dataset
found significantly higher LP ratio in pancreatic cancer patient saliva than in other patient
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Figure 4 Correlation between Leptotrichia abundance from 16S rRNA sequences and from real-time
qPCR. Cross validation of total Leptotrichia OTU abundance using real-time qPCR. After using 16S
rRNA as a reference gene for normalization of the levels of Leptotrichia genus, data was normalized
by fold change to three healthy controls with relatively low Leptotrichia OTU abundance. Each symbol
represents a patient: P = 6, and O = 12. Leptotrichia OTU abundance was correlated with qPCR fold
change according to Pearson’s correlation (r = 0.903).
groups. To verify these differences using another method, we cross-validated the relative
abundances of Leptotrichia (Fig. 4). Interestingly, during the analysis of the 16S rRNA data,
we successfully used the LP ratio to reclassify one of the patients in the non-pancreatic
cancer disease group. This particular individual had been initially diagnosed as having
an unknown digestive disease, but the patient’s high LP ratio suggested pancreatic cancer
(Fig. 3). Subsequently, the patient was re-evaluated and diagnosed with pancreatic cancer,
supporting the notion that the LP ratio may serve as a pancreatic cancer biomarker.
Despite the small cohort of patients in this study, we believe our results are especially
noteworthy because we were able to distinguish between patients with pancreatic cancer
and patients with a variety of other diseases (including non-pancreatic cancer), in addition
to healthy controls. Other researchers have proposed the use of ratios of bacterial taxa
previously. Galimanas et al. (2014) suggested using salivary bacteria abundance ratios as
a means for differentiating between healthy and diseased patients. Taxonomic ratios have
been used to differentiate between subjects in studies of obesity (Lazarevic et al., 2012),
diabetes (Zhang & Zhang, 2013), and periodontal disease (Moolya et al., 2014). Ratio
Torres et al. (2015), PeerJ, DOI 10.7717/peerj.1373 9/16
comparisons also help to control for high levels of taxonomic variability among individuals
(Ding & Schloss, 2014; Segre, 2012; Schwarzberg et al., 2014; Wang et al., 2013).
A review of the literature revealed that Leptotrichia’s role in oral health remains elusive.
However, these bacteria have been found in the bloodstream of immune-compromised
patients (Eribe & Olsen, 2008) and co-occur significantly with colorectal tumors (Warren
et al., 2013). Leptotrichia have been isolated from cardiovascular and gastrointestinal
abscesses, from systemic infections, and are thought to be pathogenic (Han & Wang,
2013). In regards to Porphyromonas, antibodies to Porphyromonas gingivalis have been
directly associated with pancreatic cancer (Michaud et al., 2012). A European cohort study
measured plasma antibodies to 25 oral bacteria in pre-diagnostic blood samples from 405
pancreatic cancer patients and 416 matched controls and found a >2-fold increase in risk
of pancreatic cancer among those with higher antibody titers to a pathogenic strain of P.
gingivalis (Michaud et al., 2012). At first glance, it appears contradictory that individuals
with higher Porphyromonas antibody titers would have lower oral abundances. However,
studies of systemic immunization of animals to particular periopathogens including
Porphyromonas have shown reduced colonization of these bacteria in the mouth and
a reduction of periodontitis (Evans et al., 1992; Persson et al., 1994; Clark et al., 1991).
Similarly, higher Porphyromonas antibody titers in individuals with pancreatic cancer may
decrease their oral abundance, though this connection needs to be formally tested.
Shifts in salivary microbial diversity could also be a systematic response to pancreatic
cancer. Pancreatic cancer is known to weaken the immune system (Von Bernstorff et al.,
2001), which could lead to overgrowth of oral bacteria and a shift towards systemically
invasive periodontal pathogens. The proliferation of bacterial pathogens could assist
cancer progression through systemic inflammation (El-Shinnawi & Soory, 2013) or
immune distraction (Feurino, Zhang & Bharadwaj, 2007). Thus, an initial increase in
Porphyromonas might be followed by a decrease due to systemic invasion and antibody
production. Indeed, inflammation is thought to play a significant role in the development
of pancreatic cancer (Farrow & Evers, 2002).
We also compared the relative abundances of several other bacterial genera that were
indicated as potential biomarkers in previous work by Farrell et al. (2012). Like Farrell et
al., we found a lower proportion of Neisseria in pancreatic cancer patient saliva compared
with the healthy and other disease category, though this trend was not significant.
However, we did not find the same results as Farrell et al. for the other bacterial genera they
identified. Our data also showed an increase in Bacteroides and decrease in the abundance
of the bacterial genus Aggregatibacter in patients with pancreatic cancer, supporting the
results of a pilot study by Lin et al. (2013), though neither trends were significant.
Methodological differences between our study and the Farrell et al. study in particular,
may partially explain our divergent results. For instance, the inability of the V4 region of
the16S rRNA gene to discriminate Streptococcus mitis from other Streptococcus species may
have prevented us from detecting difference in this species’ abundance (Farrell et al., 2012).
Additionally, our study had a broader array of patient categories and cancers were not
always confined to the pancreas at the time of sampling.
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Interestingly, since the completion of our study, Mitsuhashi et al. (2015) reported the
detection of oral Fusobacterium in pancreatic cancer tissue. A retrospective review of our
abundance data also found a lower relative abundance of Fusobacterium in pancreatic
cancer patients compared to other patient categories (Fig. 2; K–W test, P = 0.03 prior
to FDR correction) suggesting the processes driving differences in Fusobacterium may
be similar to our proposed mechanism for Porphyromonas. Although the result was not
significant after adjusting for multiple-comparisons (FDR), we suggest Fusobacterium
abundance should be considered as a potential biomarker target for future studies with
larger patient cohorts.
Overall, our study suggests that members of the salivary microbiome have promise
as potential pancreatic cancer biomarkers and we may have uncovered an important
new prospect in this regard (i.e., the LP ratio). However, our relatively small number
of samples from pancreatic cancer patients and the discrepancies between our findings
and previous work indicate that much larger patient cohorts will be needed to determine
whether salivary biomarkers are diagnostically useful. Future studies should focus on
improved metadata collection, including diet and oral health information (i.e., periodontal
disease), which would make it possible to run statistical analyses that control for multiple
factors involved in shaping oral microbial diversity. It will also be important to sample the
same individual’s saliva over time to assess whether we can distinguish between disease
stages and also to control for intra-individual variation. Further, it is possible that single
biomarkers may never be able to consistently identify pancreatic patients from other
conditions. Thus, we may need more complex metrics that combine the abundances of
multiple salivary bacteria, metabolite profiles, and detailed patient metadata. Effective
diagnostic biomarkers for pancreatic cancers have been difficult to find, but are sorely
needed and have the potential to save thousands of lives each year.
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